An observational study in Breast Cancer, sponsored by AstraZeneca. Completed at 13 sites in Austria. Open to female participants. Per ClinicalTrials.gov, last updated 2011-11-30.
Sponsored by AstraZeneca · Observational
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 57 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Hospitals, office based specialists
Exclusion Criteria:
Patient with advanced BC, already receiving Faslodex therapy
Clinical Benefit, defined as the development of at least one of the following stages and holding on for at least 6 month: Complete response, partial response or stable disease
Time frame: Baseline, after 3, 6, 9 month
Tolerability
Time frame: After 3, 6, 9 month (as per usual clinical practice)
Quality of Life
Time frame: Baseline, after 3, 6, 9 month (as per usual clinical practice)
Performance status (Karnofsky Index)
Time frame: Baseline, after 3, 6, 9 month (as per usual clinical practice)
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca